论文部分内容阅读
目的 :观察氨氯地平对慢性肾功能衰竭(CKF)病人糖耐量减退的效果。方法 :慢性肾功能衰竭病人 30例为氨氯地平组 (男性 16例 ,女性 14例 ,年龄 54a±s6a)用氨氯地平片 5mg ,po ,qd ,8wk为一个疗程 ;另设正常组 (为健康人 ) 30例 (男性15例 ,女性 15例 ;年龄 50a± 7a) ,与氨氯地平组相同作葡萄糖耐量试验及各生化指标检测 ,并作比较。结果 :氨氯地平组糖耐量试验与正常组比较呈糖耐量减退 ,治疗后好转 ,峰值左移 (由治疗前峰值 12 0min移至 60min) ;且其中 2 1例 ( 70 % )于 180min时血糖已恢复到正常值 ;治疗后血浆胰岛素升高15.7mU·L- 1± 2 .2mU·L- 1(P <0 .0 1) ;甲状旁腺激素下降 2 .1ng·L- 1± 0 .9ng·L- 1(P <0 .0 1)。结论 :氨氯地平能改善CKF病人的糖代谢紊乱
Objective: To observe the effect of amlodipine on impaired glucose tolerance in patients with chronic renal failure (CKF). Methods: Amlodipine group (16 males and 14 females, age 54a ± s6a) were treated with amlodipine 5mg, po, qd, 8wk for one course of treatment. Chronic renal failure patients were treated with amlodipine Healthy people) 30 cases (15 males and 15 females; age 50a ± 7a), the same as amlodipine group for glucose tolerance test and biochemical detection, and compared. Results: The amlodipine tolerance test showed impaired glucose tolerance compared with that of the normal group. After treatment, the glucose tolerance test improved and the peak shifted to the left (from 120 min before treatment to 60 min); and among the 21 patients (70%), the blood glucose Has returned to normal; after treatment, plasma insulin increased by 15.7mU · L- 1 ± 2. 2mU · L- 1 (P <0.01); parathyroid hormone decreased by 2.1ng · L- 1 ± 0. 9 ng · L -1 (P <0.01). Conclusion: Amlodipine can improve the disorder of glucose metabolism in CKF patients